Article Versions Notes

Balakirouchenane D, Guégan S, Csajka C, Jouinot A, Heidelberger V, Puszkiel A, Zehou O, Khoudour N, Courlet P, Kramkimel N, et al. Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. Cancers. 2020; 12(4):931. https://doi.org/10.3390/cancers12040931

Balakirouchenane, David, Sarah Guégan, Chantal Csajka, Anne Jouinot, Valentine Heidelberger, Alicja Puszkiel, Ouidad Zehou, Nihel Khoudour, Perrine Courlet, Nora Kramkimel, and et al. 2020. "Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma" Cancers 12, no. 4: 931. https://doi.org/10.3390/cancers12040931

Balakirouchenane, D., Guégan, S., Csajka, C., Jouinot, A., Heidelberger, V., Puszkiel, A., Zehou, O., Khoudour, N., Courlet, P., Kramkimel, N., Lheure, C., Franck, N., Huillard, O., Arrondeau, J., Vidal, M., Goldwasser, F., Maubec, E., Dupin, N., Aractingi, S., ... Blanchet, B. (2020). Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. Cancers, 12(4), 931. https://doi.org/10.3390/cancers12040931